Hansa Biopharma

• Hansa Biopharma, a commercial-stage biotechnology company focused on developing treatments for patients with rare immunological conditions, successfully raised SEK 672 million in equity financing, upsized from c. SEK 565 million at launch
• The transaction was launched on the back of topline Phase III data for the lead asset, imlifidase, in desensitization of highly sensitized patients ahead of kidney transplant which yielded an increase in Hansa Biopharma’s market capitalization of over 25% until transaction launch
• The capital increase was priced at SEK 39.50 per share which corresponds to a discount of only 0.3% vis-a-vis the preceding 5-day VWAP
• Hansa Biopharma intends to use the net proceeds from this offering for general corporate purposes, including the support for the potential filing of a BLA with the FDA before year-end 2025, building out medical affairs, market access and commercial capabilities in the US in preparation for the potential commercial launch of imlifidase in 2026, subject to approval, a possible supplemental BLA filing for anti-GBM, as well as other general operating expenses
• Van Lanschot Kempen acted as Joint Bookrunner and is proud to have contributed to a multiple times covered order book and to have supported Hansa Biopharma for the third time in five years

• Hansa Biopharma is focusing on developing innovative and life-altering treatments for patients with rare immunological conditions
• Their lead asset, imlifidase (Idefirix®), already received accelerated approval by the EMA for the desensitization of highly sensitized patients ahead of kidney transplant
• The company’s broader pipeline includes an anticipated Phase III readout for imlifidase in anti-GBM by end-2025, the recent completion of a Phase II trial in Guillain-Barré syndrome, and a planned FDA meeting in Q1 2026 to determine the clinical development path for its repeat-dose candidate, HNSA-5487
• Hansa Biopharma is headquartered in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: HNSA)

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Bookrunner in the USD 345 million Capital Increase by uniQure
• Joint Bookrunner in the secondary sell-down of existing BioArctic shares for SEK 720 million
• Financial Adviser to Galapagos in the sale of a portfolio of oncology and immunology programmes to Onco3R
• Co-Manager in the USD 748 million Capital Increase by Abivax
• Financial Adviser in MaaT Pharma’s €38 million venture debt facility from the European Investment Bank
• Joint Bookrunner in the USD 201 million Capital Increase by Pharvaris
• Lead Manager in the USD 345 million Capital Increase by Merus
• Co-Placement Agent in DBV Technologies’ up to USD 307 million financing
• Placement Agent in MaaT Pharma’s €13 million capital increase
• Sole Financial Adviser in Pharming’s SEK 725 million public takeover of Abliva
• Sole Financial Adviser in GENFIT’s royalty financing up to €185 million
• Sole Financial Adviser in IO Biotech’s c. €58 million loan facility from the European Investment Bank
• Financial Adviser in the USD 479 million US Public Offering by NewAmsterdam Pharma
• Sole Financial Adviser to SNIPR Biome in securing a €20 million venture debt facility from the European Investment Bank